Giuseppina Biondi

Giuseppina Biondi

Auto-generated profile, based on publicly available information

Giuseppina Biondi

Section of Internal Medicine, Endocrinology, Andrology and Metabolic Diseases, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari Aldo Moro, Bari, Italy

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
GPGiuseppe Palma
Giuseppe Palma
GSGian Pio Sorice
Gian Pio Sorice
VGValentina Annamaria Genchi
Valentina Annamaria Genchi
FGFiorella Giordano
Fiorella Giordano
CCCristina Caccioppoli
Cristina Caccioppoli
SPSebastio Perrini
Sebastio Perrini
Obesity is a chronic disease caused by an excess of adipose tissue that may impair health by altering the functionality of various organs, including the lungs. Excessive deposition of fat in the abdominal area can lead to abnormal positioning of the diaphragm and consequent reduction in lung volume, leading to a heightened demand for ventilation and increased exposure to respiratory diseases, such as chronic obstructive pulmonary disease, asthma, and obstructive sleep apnoea. In addition to mechanical ventilatory constraints, excess fat and ectopic deposition in visceral depots can lead to adipose tissue dysfunction, which promotes metabolic disorders. An altered adipokine-secretion profile from dysfunctional adipose tissue in morbid obesity fosters systemic, low-grade inflammation, impairing pulmonary immune response and promoting airway hyperresponsiveness. A potential target of these adipokines could be the NLRP3 inflammasome, a critical component of the innate immune system, the harmful pro-inflammatory effect of which affects both adipose and lung tissue in obesity. In this review, we will investigate the crosstalk between adipose tissue and the lung in obesity, highlighting the main inflammatory mediators and novel therapeutic targets in preventing pulmonary dysfunction.

Verified
Journal Article
Open access
PDF file
GBGiuseppina Biondi
Giuseppina Biondi
Nicola MarranoNicola Marrano
Nicola Marrano
ABAnna Borrelli
Anna Borrelli
MRMartina Rella
Martina Rella
GPGiuseppe Palma
Giuseppe Palma
Annalisa NatalicchioAnnalisa Natalicchio
Annalisa Natalicchio
The dysregulation of the β-cell functional mass, which is a reduction in the number of β-cells and their ability to secure adequate insulin secretion, represents a key mechanistic factor leading to the onset of type 2 diabetes (T2D). Obesity is recognised as a leading cause of β-cell loss and dysfunction and a risk factor for T2D. The natural history of β-cell failure in obesity-induced T2D can be divided into three steps: (1) β-cell compensatory hyperplasia and insulin hypersecretion, (2) insulin secretory dysfunction, and (3) loss of β-cell mass. Adipose tissue (AT) secretes many hormones/cytokines (adipokines) and fatty acids that can directly influence β-cell function and viability. As this secretory pattern is altered in obese and diabetic patients, it is expected that the cross-talk between AT and pancreatic β-cells could drive the maintenance of the β-cell integrity under physiological conditions and contribute to the reduction in the β-cell functional mass in a dysmetabolic state. In the current review, we summarise the evidence of the ability of the AT secretome to influence each step of β-cell failure, and attempt to draw a timeline of the alterations in the adipokine secretion pattern in the transition from obesity to T2D that reflects the progressive deterioration of the β-cell functional mass.

16 January 2023 in Biomolecules
Verified
Journal Article
Open access
PDF file
Nicola MarranoNicola Marrano
Nicola Marrano
GBGiuseppina Biondi
Giuseppina Biondi
ABAnna Borrelli
Anna Borrelli
MRMartina Rella
Martina Rella
TZTommaso Zambetta
Tommaso Zambetta
Annalisa NatalicchioAnnalisa Natalicchio
Annalisa Natalicchio
Type 2 diabetes (T2D) and Alzheimer’s diseases (AD) represent major health issues that have reached alarming levels in the last decades. Although growing evidence demonstrates that AD is a significant comorbidity of T2D, and there is a ~1.4–2-fold increase in the risk of developing AD among T2D patients, the involvement of possible common triggers in the pathogenesis of these two diseases remains largely unknown. Of note, recent mechanistic insights suggest that lipotoxicity could represent the missing ring in the pathogenetic mechanisms linking T2D to AD. Indeed, obesity, which represents the main cause of lipotoxicity, has been recognized as a major risk factor for both pathological conditions. Lipotoxicity can lead to inflammation, insulin resistance, oxidative stress, ceramide and amyloid accumulation, endoplasmic reticulum stress, ferroptosis, and autophagy, which are shared biological events in the pathogenesis of T2D and AD. In the current review, we try to provide a critical and comprehensive view of the common molecular pathways activated by lipotoxicity in T2D and AD, attempting to summarize how these mechanisms can drive future research and open the way to new therapeutic perspectives.

Verified
Journal Article
Open access
PDF file
RDRossella D’oria
Rossella D’oria
VGValentina Annamaria Genchi
Valentina Annamaria Genchi
CCCristina Caccioppoli
Cristina Caccioppoli
ICIsabella Calderoni
Isabella Calderoni
Nicola MarranoNicola Marrano
Nicola Marrano
LLLuigi Laviola
Luigi Laviola
Obesity with its associated complications represents a social, economic and health problem of utmost importance worldwide. Specifically, obese patients carry a significantly higher risk of developing cardiovascular disease compared to nonobese individuals. Multiple molecular mechanisms contribute to the impaired biological activity of the distinct adipose tissue depots in obesity, including secretion of proinflammatory mediators and reactive oxygen species, ultimately leading to an unfavorable impact on the cardiovascular system. This review summarizes data relating to the contribution of the main adipose tissue depots, including both remote (i.e., intra-abdominal, hepatic, skeletal, pancreatic, renal, and mesenteric adipose fat), and cardiac (i.e., the epicardial fat) adipose locations, on the cardiovascular system. Finally, we discuss both pharmacological and non-pharmacological strategies aimed at reducing cardiovascular risk through acting on adipose tissues, with particular attention to the epicardial fat.

19 November 2019 in Diabetes/Metabolism Research and Reviews
Verified
Journal Article
Closed access
PDF file
Annalisa NatalicchioAnnalisa Natalicchio
Annalisa Natalicchio
Nicola MarranoNicola Marrano
Nicola Marrano
GBGiuseppina Biondi
Giuseppina Biondi
LDLucia Dipaola
Lucia Dipaola
RSRosaria Spagnuolo
Rosaria Spagnuolo
Francesco GiorginoFrancesco Giorgino
Francesco Giorgino

21 February 2022 in Frontiers in Endocrinology
Verified
Journal Article
Open access
Angelo CignarelliAngelo Cignarelli
Angelo Cignarelli
VGValentina Annamaria Genchi
Valentina Annamaria Genchi
GGGiulia Le Grazie
Giulia Le Grazie
ICIrene Caruso
Irene Caruso
Nicola MarranoNicola Marrano
Nicola Marrano
Francesco GiorginoFrancesco Giorgino
Francesco Giorgino
Accumulating evidence supports the early use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium glucose transporter-2 inhibitors (SGLT-2is) for the treatment of type 2 diabetes. Indeed, these compounds exert numerous pleiotropic actions that favorably affect metabolism and diabetes comorbidities, showing an additional effect beyond glucose control. Although a substantial amount of knowledge has been generated regarding the mechanism of action of both drug classes, much remains to be understood. Growth hormone (GH) is an important driver for multiple endocrine responses involving changes in glucose and lipid metabolism, and affects several tissues and organs (e.g., bone, heart). It acts directly on several target tissues, including skeletal muscle and bone, but several effects are mediated indirectly by circulating (liver-derived) or locally produced IGF-1. In consideration of the multiple metabolic and cardiovascular effects seen in subjects treated with GLP-1RAs and SGLT-2is (e.g., reduction of hyperglycemia, weight loss, free/fat mass and bone remodeling, anti-atherosclerosis, natriuresis), it is reasonable to speculate that GH and IGF-1 may play a about a relevant role in this context. This narrative mini-review aims to describe the involvement of the GH/IGF-1/IGF-1R axis in either mediating or responding to the effects of each of the two drug classes.